AxoGen (AXGN) Given a $38.00 Price Target by Lake Street Capital Analysts
Lake Street Capital set a $38.00 price objective on AxoGen (NASDAQ:AXGN) in a report released on Friday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.
AXGN has been the topic of several other research reports. Leerink Swann increased their target price on AxoGen from $23.00 to $26.00 and gave the company an outperform rating in a report on Thursday, November 2nd. Wedbush reissued a buy rating and issued a $27.00 target price (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Jefferies Group initiated coverage on AxoGen in a report on Thursday, November 30th. They issued a buy rating and a $35.00 target price on the stock. Cantor Fitzgerald reissued an overweight rating on shares of AxoGen in a report on Friday, January 5th. Finally, BidaskClub lowered AxoGen from a strong-buy rating to a buy rating in a report on Thursday, January 11th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $31.71.
AxoGen (AXGN) traded down $1.00 during trading on Friday, hitting $32.95. The stock had a trading volume of 485,207 shares, compared to its average volume of 334,815. AxoGen has a 1-year low of $9.55 and a 1-year high of $35.40. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93. The stock has a market capitalization of $1,171.17, a price-to-earnings ratio of -109.83 and a beta of 0.10.
In related news, Director Jamie Mark Grooms sold 63,395 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $27.67, for a total value of $1,754,139.65. Following the transaction, the director now owns 5,827 shares of the company’s stock, valued at $161,233.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 313,397 shares of company stock worth $8,386,910 in the last three months. 9.33% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. Pennsylvania Trust Co grew its holdings in shares of AxoGen by 7.0% during the fourth quarter. Pennsylvania Trust Co now owns 152,370 shares of the medical equipment provider’s stock worth $4,312,000 after purchasing an additional 10,000 shares during the last quarter. Neuberger Berman Group LLC grew its holdings in shares of AxoGen by 133.3% during the third quarter. Neuberger Berman Group LLC now owns 28,000 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 16,000 shares during the last quarter. California Public Employees Retirement System grew its holdings in shares of AxoGen by 4.9% during the third quarter. California Public Employees Retirement System now owns 137,536 shares of the medical equipment provider’s stock worth $2,661,000 after purchasing an additional 6,436 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of AxoGen by 26.6% during the second quarter. New York State Common Retirement Fund now owns 31,400 shares of the medical equipment provider’s stock worth $526,000 after purchasing an additional 6,599 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its holdings in shares of AxoGen by 91.8% during the third quarter. Campbell & CO Investment Adviser LLC now owns 37,961 shares of the medical equipment provider’s stock worth $735,000 after purchasing an additional 18,166 shares during the last quarter. 69.57% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/axogen-axgn-given-a-38-00-price-target-by-lake-street-capital-analysts/1905304.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.